Evaluation and Management of Opioid Dependence in Pregnancy

Psychosomatics

Volumn 53, Issue 5, 2012, Pages 424-432

  Park, Eliza M ^a   Meltzer Brody, Samantha ^a   Suzuki, Joji ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; OPIATE; NARCOTIC ANALGESIC AGENT;

BIRTH WEIGHT; BREAST FEEDING; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; FETUS RISK; HEAD CIRCUMFERENCE; HEART RATE; HUMAN; LIAISON PSYCHIATRY; LOW DRUG DOSE; MEDICAL EDUCATION; MOTOR ACTIVITY; OPIATE ADDICTION; PREGNANT WOMAN; PREMATURE LABOR; PSYCHIATRIST; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; WITHDRAWAL SYNDROME; ANALGESIA; FEMALE; MENTAL DISEASE; METHODOLOGY; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PREGNANCY COMPLICATION;

ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; MENTAL DISORDERS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; PREGNANCY; PREGNANCY COMPLICATIONS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84873039077     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2012.04.003     Document Type: Review

References (61)

1. Ludlow J., Christmas T., Paech M.J., Orr B. Drug abuse and dependency during pregnancy: anaesthetic issues. Anaesth Intensive Care 2007, 35(6):881-893.
2. Results from the 2009 National Survey on Drug Use and Health. Summary of National Findings 2010, Volume I. SAMHSA, Rockville, MD.
3. Fischer G., Bitschnau M., Peternell A., Eder H., Topitz A. Pregnancy and substance abuse. Arch Womens Ment Health 1999, 2:57-65.
4. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 1998, 25(1):139-151.
5. Wong S., Ordean A., Kahan M. Substance use in pregnancy. J Obstet Gynaecol Can 2011, 33(4):367-384.
6. Bell J., Harvey-Dodds L. Pregnancy and injecting drug use. BMJ 2008, 336(7656):1303-1305.
7. Higgins P.G., Clough D.H., Frank B., Wallerstedt C. Changes in health behaviors made by pregnant substance users. Int J Addict 1995, 30(10):1323-1333.
8. Rayburn W.F., Bogenschutz M.P. Pharmacotherapy for pregnant women with addictions. Am J Obstet Gynecol 2004, 191(6):1885-1897.
9. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010, 363(24):2320-2331.
10. Christensen C. Management of chemical dependence in pregnancy. Clin Obstet Gynecol 2008, 51(2):445-455.
11. Diagnostic and statistical manual of mental disorders: DSM-IV-TR 2000, American Psychiatric Association, American Psychiatric Publishing, Inc.
12. Broussard C.S., Rasmussen S.A., Reefhuis J., Friedman J.M., Jann M.W., Riehle-Colarusso T., et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011, 204(4). 314 e1-e11.
13. Finnegan L.P. Treatment issues for opioid-dependent women during the perinatal period. J Psychoactive Drugs 1991, 23(2):191-201.
14. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., et al. Methadone vs. buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006, 101(2):275-281.
15. Schmittner J., Schroeder J.R., Epstein D.H., Preston K.L. Menstrual cycle length during methadone maintenance. Addiction 2005, 100(6):829-836.
16. Velez M., Jansson L.M. The Opioid-dependent mother and newborn dyad: non-pharmacologic care. J Addict Med 2008, 2(3):113-120.
17. Lacroix I., Berrebi A., Garipuy D., Schmitt L., Hammou Y., Chaumerliac C., et al. Buprenorphine vs. methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011.
18. Martin P.R., Arria A.M., Fischer G., Kaltenbach K., Heil S.H., Stine S.M., et al. Psychopharmacologic management of opioid-dependent women during pregnancy. Am J Addict 2009, 18(2):148-156.
19. Unger A., Jung E., Winklbaur B., Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis 2010, 29(2):217-230.
20. Fitzsimons H.E., Tuten M., Vaidya V., Jones H.E. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat 2007, 32(1):19-25.
21. Jones H.E., Martin P.R., Heil S.H., Kaltenbach K., Selby P., Coyle M.G., et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008, 35(3):245-259.
22. Prenatal Substance Exposure 2008, National AIA Resource Center.
23. Bhuvaneswar C.G., Chang G., Epstein L.A., Stern T.A. Cocaine and opioid use during pregnancy: prevalence and management. Primary care companion to J Clin Psychiatry 2008, 10(1):59-65.
24. Zuspan F.P., Gumpel J.A., Mejia-Zelaya A., Madden J., Davis R. Fetal stress from methadone withdrawal. Am J Obstet Gynecol 1975, 122(1):43-46.
25. Rementeria J.L., Nunag N.N. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973, 116(8):1152-1156.
26. Dashe J.S., Jackson G.L., Olscher D.A., Zane E.H., Wendel G.D. Opioid detoxification in pregnancy. Obstet Gynecol 1998, 92(5):854-858.
27. Luty J., Nikolaou V., Bearn J. Is opiate detoxification unsafe in pregnancy?. J Subst Abuse Treat 2003, 24(4):363-367.
28. Public Policy Statement on Women, Alcohol and Other Drugs, and Pregnancy 2011, American Society of Addiction Medicine, American Society of Addiction Medicine, Inc., Chevy Chase, MD.
29. Connaughton J.F., Reeser D., Schut J., Finnegan L.P. Perinatal addiction: outcome and management. Am J Obstet Gynecol 1977, 129(6):679-686.
30. Johnson B, Shaw I: Medication-assisted treatment for opioid addiction in opioid treatment programs. No:(SMA) 05-4048. 2005:351.
31. Kandall S.R., Albin S., Lowinson J., Berle B., Eidelman A.I., Gartner L.M. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976, 58(5):681-685.
32. Archie C. Methadone in the management of narcotic addiction in pregnancy. Curr Opin Obstet Gynecol 1998, 10(6):435-440.
33. Farid W.O., Dunlop S.A., Tait R.J., Hulse G.K. The effects of maternally administered methadone, buprenorphine, and naltrexone on offspring: review of human and animal data. Current Neuropharmacol 2008, 6(2):125-150.
34. About Buprenorphine Therapy SAMHSA, Accessed August 8, 2011. http://www.Buprenorphine.samhsa.gov.
35. Clinical Guidelines for the use of buprenorphine in the treatment of opioid addiction 2004, Center for Substance Abuse Treatment, DHHS, Rockville, MD.
36. Jones H.E., Suess P., Jasinski D.R., Johnson R.E. Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study. Am J Addict 2006, 15(1):61-70.
37. Schindler S.D., Eder H., Ortner R., Rohrmeister K., Langer M., Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003, 98(1):103-110.
38. Kahila H., Saisto T., Kivitie-Kallio S., Haukkamaa M., Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007, 86(2):185-190.
39. Johnson R.E., Jones H.E., Jasinski D.R., Svikis D.S., Haug N.A., Jansson L.M., et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001, 63(1):97-103.
40. Jones H.E., Johnson R.E., Jasinski D.R., O'Grady K.E., Chisholm C.A., Choo R.E., et al. Buprenorphine vs. methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005, 79(1):1-10.
41. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008, 96(1/2):69-78.
42. Binder T., Vavrinkova B. Prospective randomized comparative study of the effect of buprenorphine, methadone, and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008, 29(1):80-86.
43. Simmat-Durand L., Lejeune C., Gourarier L. Pregnancy under high-dose buprenorphine. Eur J Obstet Gynecol Reprod Biol 2009, 142(2):119-123.
44. Jansson L.M., Dipietro J.A., Velez M., Elko A., Williams E., Milio L., et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011, 33(2):240-243.
45. Cleary B.J., Donnelly J.M., Strawbridge J.D., Gallagher P.J., Fahey T., White M.J., et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011, 204(2). 139 e1-e9.
46. Konijnenberg C., Melinder A. Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development. Child Neuropsy 2011, 17(5):495-519.
47. Malek A., Mattison D.R. Drugs and medicines in pregnancy: the placental disposition of opioids. Curr Pharmaceut Biotechnol 2011, 12(5):797-803.
48. Rosen T.S., Johnson H.L. Children of methadone-maintained mothers: follow-up to 18 months of age. J Pediatr 1982, 101(2):192-196.
49. Marcus J., Hans S.L., Jeremy R.J. A longitudinal study of offspring born to methadone-maintained women. III. Effects of multiple risk factors on development at 4, 8, and 12 months. Am J Drug Alcohol Abuse 1984, 10(2):195-207.
50. Ornoy A., Segal J., Bar-Hamburger R., Greenbaum C. Developmental outcome of school-age children born to mothers with heroin dependency: importance of environmental factors. Dev Med Child Neurol 2001, 43(10):668-675.
51. Wilson G.S., Desmond M.M., Wait R.B. Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr 1981, 98(5):716-722.
52. Yanai J., Huleihel R., Izrael M., Metsuyanim S., Shahak H., Vatury O., et al. Functional changes after prenatal opiate exposure related to opiate receptors' regulated alterations in cholinergic innervation. Int J Neuropsychopharmacol 2003, 6(3):253-265.
53. Jansson L.M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009, 5(1):47-55.
54. Alford D.P., Compton P., Samet J.H. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006, 144(2):127-134.
55. Meyer M., Paranya G., Keefer Norris A., Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain 2010, 14(9):939-943.
56. Meyer M., Wagner K., Benvenuto A., Plante D., Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007, 110(2 Pt 1):261-266.
57. Jones H.E., O'Grady K., Dahne J., Johnson R., Lemoine L., Milio L., et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009, 35(3):151-156.
58. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008, 103(9):1429-1440.
59. Finkelstein N. Treatment issues for alcohol- and drug-dependent pregnant and parenting women. Health Soc Work 1994, 19(1):7-15.
60. Jones H.E., Haug N., Silverman K., Stitzer M., Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend 2001, 61(3):297-306.
61. Substance Abuse During Pregnancy. State Policies in Brief 2011, Alan Guttmacher Institute.